@nejm : Late breaking at #AHA23: In the ARTESIA trial involving patients with subclinical (typically asymptomatic) #AFib, apixaban led to a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. Full trial results: nej.md/3sqCbJ1 • TwiCopy

NEJM

@nejm

+ Follow

The New England Journal of Medicine is the world’s leading medical journal and website.

ID: 25950355

linkhttp://NEJM.org calendar_today23-03-2009 04:10:07

32,32K Tweet

946,946K Followers

437 Following

NEJM

@nejm

a year ago

Late breaking at #AHA23: In the ARTESIA trial involving patients with subclinical (typically asymptomatic) #AFib, apixaban led to a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. Full trial results: nej.md/3sqCbJ1

thumb_up_off_alt447

chat_bubble_outline3

repeat147

shareShare